The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas

Area of Science:

• Oncology
• Cancer Metabolism
• Pharmacology

Background:

• Sarcoma cell lines exhibit resistance to epidermal growth factor receptor (EGFR) inhibitor gefitinib monotherapy.
• PENAO, a novel anti-tumor metabolic compound, is currently undergoing clinical trials.
• EGFR signaling and tumor metabolism pathways positively regulate tumor energy production.

Purpose of the Study:

• To investigate the combined therapeutic effects of gefitinib and PENAO in sarcoma.
• To elucidate the mechanisms underlying the combination therapy's efficacy.
• To evaluate the combination therapy's impact on sarcoma cell proliferation, death, and mitochondrial function in vitro and in vivo.

Main Methods:

• In vitro studies using sarcoma cell lines to assess proliferation and cell death.
• Mitochondrial function analysis post-treatment.
• In vivo studies in mice to evaluate tumor growth delay, survival, and toxicity.
• Dose- and time-dependent synergy assessments.

Main Results:

• PENAO monotherapy reduced proliferation in 12 sarcoma cell lines.
• Combined gefitinib and PENAO demonstrated synergistic inhibition in a time- and dose-dependent manner in 3 sarcoma cell lines.
• Combined treatment significantly enhanced cell death and perturbed mitochondrial function.
• In vivo combination therapy was non-toxic, significantly delayed tumor growth, and prolonged survival.

Conclusions:

• The combination of PENAO and gefitinib exhibits synergistic anti-tumor activity against sarcoma in vitro and in vivo.
• This combination therapy effectively reduces tumor growth and improves survival without significant toxicity.
• Gefitinib and PENAO combination represents a promising treatment strategy for sarcoma.